Update on the Phase 2 REBALANCE-HF Trial of SAVM for HFpEF/HFmrEF: Lessons Learned and Future Directions

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Grant Support/Research Contract - National Institutes of Health; Actelion; AstraZenca; Corvia; Novartis; Pfizer
• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Actelion; AstraZenca; Amgen; Aria CV; Axon Therapies; Bayer AG; Boehringer-Ingelheim; Boston Scientific Corporation; Bristol-Myers Squibb; Cardiora; Coridea; CVRx; Cyclerion; Cytokinetics; Edwards Lifesciences; Eidos; Eisai; Imara; Impulse Dynamics; GSK; Intellia; Ionis; Ironwood; Lilly; Merck; MyoKardia; Novartis; Novo Nordisk; Pfizer; Prothena; Regeneron; Rivus; Sanofi-Aventis; Sardocor; Shifamed; Tenax; Tenaya; United Therapeutics